Magnifying LeNS Archives - Page 4 of 7

GO2 for Lung Cancer’s Presence at The World Conference on Lung Cancer 2022

Bethany Johnson (GO2 for Lung Cancer)2022-10-27T10:02:18-05:00October 27th, 2022|Hot Topics, Magnifying LeNS, Newsletter Articles, Science and Research|

Author: Brittney Nichols, MPH, BSN-RN, Specialist, Science and Research This summer, the World Conference on Lung Cancer convened in Vienna, Austria. GO2 shared our research with this community as both lead authors and collaborators on several projects to help [...]

1

Advances in Treatment for Early Stage Non-Small Cell Lung Cancer

Bethany Johnson (GO2 for Lung Cancer)2022-10-27T09:52:39-05:00October 27th, 2022|Hot Topics, Magnifying LeNS, Newsletter Articles, Science and Research|

Author: Daniel A. Saez, MSc, Manager, LungMATCH Navigation Program For many years, the treatment options given to patients diagnosed with early stage non-small cell lung cancer (NSCLC) was limited to surgery with or without chemotherapy to improve outcomes. However, [...]

0

Targeted Therapy Treatment Updates from ASCO 2022

Bethany Johnson (GO2 for Lung Cancer)2022-06-27T06:58:14-05:00June 27th, 2022|Hot Topics, Magnifying LeNS, Newsletter Articles, Science and Research|

Author: Andrew Ciupek, PhD, Associate Director, Clinical Research Targeted therapy research was front and center at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. Data was presented from several studies detailing new targeted therapies and better understanding [...]

1

New Treatments on the Horizon for Small Cell Lung Cancer

Bethany Johnson (GO2 for Lung Cancer)2023-09-20T12:45:03-05:00June 27th, 2022|Hot Topics, Magnifying LeNS, Newsletter Articles, Science and Research, Small Cell Lung Cancer|

Author: Jennifer C. King, PhD, Chief Scientific Officer People diagnosed with small cell lung cancer (SCLC) have historically had limited treatment options—but researchers are working to change that. At the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, [...]

0

Immunotherapy Treatment Updates from ASCO 2022: Combinations, Resistance and More

Bethany Johnson (GO2 for Lung Cancer)2022-06-27T06:45:18-05:00June 27th, 2022|Hot Topics, Magnifying LeNS, Newsletter Articles, Science and Research|

Author: Daniel A. Saez, MSc, Manager, LungMATCH Navigation Program Many patients with non-small cell lung cancer (NSCLC) rely on a class of treatments called immunotherapy to battle their cancer. The significant difference between immunotherapy and targeted therapy (the other [...]

1

Coming Together for Equitable Cancer Care

Bethany Johnson (GO2 for Lung Cancer)2022-06-27T06:39:23-05:00June 27th, 2022|Hot Topics, Magnifying LeNS, Newsletter Articles, Science and Research|

Author: Daniel A. Saez, MSc, Manager, LungMATCH Navigation Program One of the priorities of GO2 for Lung Cancer, alongside many other ally organizations, is to ensure that people diagnosed with lung cancer receive optimal care regardless of their background, [...]

0

Treatments Beyond Surgery: Early-stage Options from ASCO 2022

Bethany Johnson (GO2 for Lung Cancer)2022-06-27T06:16:53-05:00June 27th, 2022|Hot Topics, Magnifying LeNS, Newsletter Articles, Science and Research|

Authors: Andrew Ciupek, PhD, Associate Director, Clinical Research and Daniel A. Saez, MSc, Manager, LungMATCH Navigation Program People who are diagnosed with early stage (stage 1-2) non-small cell lung cancer (NSCLC) are generally broken down into two groups: those [...]

0

Small Cell Lung Cancer Transformation: What Is It and How Do We Treat It?

Bethany Johnson (GO2 for Lung Cancer)2023-09-20T12:45:20-05:00April 28th, 2022|Hot Topics, Magnifying LeNS, Newsletter Articles, Science and Research, Small Cell Lung Cancer|

Author: Daniel A. Saez, MSc, Manager, LungMATCH Navigation Program, GO2 for Lung Cancer People with lung cancer receiving treatment may encounter acquired drug resistance—a reduction in treatment effectiveness over time. Tagrisso (osimertinib) is currently a frontline treatment for people [...]

1

Immune Checkpoint Inhibitor Resistance: What To Do Next?

Bethany Johnson (GO2 for Lung Cancer)2022-04-28T09:02:18-05:00April 28th, 2022|Magnifying LeNS, Newsletter Articles, Science and Research|

Author: Daniel A. Saez, MSc, Manager, LungMATCH Navigation Program, GO2 for Lung Cancer Immunotherapy, a type of treatment that helps the body’s own immune system fight cancer, is often discussed as a first line of treatment for people with [...]

0

New Screening Guidelines: How They Affect You and What You Need To Know

Bethany Johnson (GO2 for Lung Cancer)2022-04-28T09:00:22-05:00April 28th, 2022|Magnifying LeNS, News, Newsletter Articles, Science and Research|

Authors: Andrew Ciupek, PhD, Associate Director, Clinical Research, GO2 for Lung Cancer; Anita K. McGlothlin, Senior Director, Economics & Health Policy, GO2 for Lung Cancer; Angela Criswell, MA, CPS, Director, Quality Screening and Program Initiatives, GO2 for Lung Cancer [...]

1